Hemab Therapeutics Holdings, Inc.
COAGNext catalyst
HMB-002 (Part A)
Von Willebrand Disease (VWD)
Get an email about COAG's next catalysts
Track Hemab Therapeutics Holdings (COAG) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
COAG Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.51 | FQ end Sep/2026 | Call: bmo
HMB-002 (Part A) Phase 2 Est. Readout
Primary completion for HMB-002 (Part A) trial (NCT06754852) in Von Willebrand Disease (VWD)
SourceHMB-001 Phase 2 Est. Readout
Primary completion for HMB-001 trial (NCT06211634) in Glanzmann Thrombasthenia
SourceMarket Overview
Stock performance and key metrics
Sutacimig
Congenital Factor VII Deficiency
HMB-002 (Part A)
Von Willebrand Disease (VWD)
HMB-001
Glanzmann Thrombasthenia
HMB-002 (Part B)
Von Willebrand Disease (VWD)
HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
Von Willebrand Disease (VWD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sutacimig | Phase 2 | Congenital Factor VII Deficiency | - | - |
HMB-002 (Part A) | Phase 2 | Von Willebrand Disease (VWD) | - | - |
HMB-001 | Phase 2 | Glanzmann Thrombasthenia | - | - |
HMB-002 (Part B) | Phase 2 | Von Willebrand Disease (VWD) | - | - |
HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) | Phase 2 | Von Willebrand Disease (VWD) | - | - |
Frequently asked questions
What is in Hemab Therapeutics Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Hemab Therapeutics Holdings, Inc.'s (COAG) pipeline across Phase 2. Its lead program is HMB-001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hemab Therapeutics Holdings, Inc.'s next FDA catalyst?→
Hemab Therapeutics Holdings, Inc.'s (COAG) next tracked catalyst is a Phase 2 readout expected July 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track COAG biotech catalysts?→
Add COAG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hemab Therapeutics Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.